All News

"Major complications of ring pessaries are rare but present considerable challenges to surgeons and patients when they do occur," write E. Mackenzie Gibbs, MD, and Charles Lloyd Secrest, MD.

A recap of the FDA submissions and regulatory decisions in urology from July 2025.

Data showed that fracture risk rises briefly after menopausal hormone therapy discontinuation, then falls below never-users.

The expanded labeling would enable the use of flibanserin to treat hypoactive sexual desire disorder in postmenopausal women.

In a panel meeting convened by the FDA, experts urged the agency to revise or remove the outdated boxed warning on hormone therapies for menopause.

Take a look back through some of the top stories from the first half of the year.

Oral sulopenem was approved by the FDA in October 2024 for the management of uUTIs.

The CELLEBRATE trial is aiming to provide additional evidence to support the safety and efficacy of iltamiocel.

"I’m hopeful because women in urology are no longer an exception—they’re becoming the norm," says Shaya Taghechian, MD.

Rachel Rubin, MD, discusses advancements in sexual health education and guidelines at the AUA meeting.

In this episode, guideline chair Melissa Kaufman, MD, PhD, FACS, highlights key points from the new AUA GSM guideline and illustrates its impact for clinical management of this condition.

"The biggest message from this study is that 60% can expect resolution of UUI, simply by fixing the prolapse and placing a sling, which is not normally indicated for UUI," according to Christina M. Mezes, DO, and Catherine A. Matthews, MD.

A recap of the FDA submissions and regulatory decisions in urology from March 2025.

The test can deliver diagnostic results for chlamydia, gonorrhea, and trichomoniasis.

"I think [gepotidacin] gives a different side effect profile available to the clinicians, and I think for patients as well, it provides a better, more durable option over time," says Ryan Haumschild, PharmD, MS, MBA, CPEL.

The approval is supported by data from the phase 3 EAGLE-2 and EAGLE-3 trials.

"The findings from this study will help us understand sunobinop’s potential as a possible new treatment option for this chronic disorder,” said Craig Landau, MD.

Age, race, and hormonal contraceptive use did not significantly impact the efficacy of sildenafil cream, 3.6%, in female sexual arousal disorder.

“These findings support the safety of vaginal estrogen for treatment of local menopause symptoms, even in high-risk women,” says Gabriella M. Rustia, MD.

Data showed that vaginal estrogen, vaginal DHEA, oral ospemifene, and vaginal moisturizers may provide benefit in the management of symptoms related to GSM.

The company expects the device to become available for US patients with pelvic organ prolapse in September 2024.

There were no differences in the number of treatment-related TEAEs in patients who received sildenafil cream vs patients who received placebo.

In this episode of Speaking of Urology®, Ashley G. Winter, MD, discusses the use of vaginal estrogen.

Developed by the AUGS Scientific Committee and Research Agenda Writing Group

The FDA approval is supported by data from the phase 3 ALLIUM trial, which demonstrated the non-inferiority and superiority of cefepime/enmetazobactam vs piperacillin/tazobactam.

The aim of this document is to present a framework by which AUGS and its members can address the development of new technology and techniques, particularly in the surgical arena.

The FDA has issued a complete response letter regarding a new drug application for cefepime-taniborbactam for the treatment of patients with complicated urinary tract infection.

The position statement is meant to iterate AUGS' support for gender inclusion of both patients and health care providers.

Cefepime-taniborbactam is currently under review by the FDA for cUTI, including acute pyelonephritis, based on data from the CERTAIN-1 trial.